Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
23 November 2023 - 12:05AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced its participation in the 6th Annual Evercore ISI
HealthCONx Conference held in Miami.
Brian Sullivan, Chairman, Chief Executive Officer, and
Co-founder of Celcuity, is scheduled for a fireside chat at 12:30
p.m. ET on Wednesday, November 29, 2023. A live webcast of the
event will be available using this weblink:
https://wsw.com/webcast/evercore39/celc/2327201. Alternatively, the
live webcast will be accessible from the Investors section of the
company's website at https://ir.celcuity.com/events-presentations/
with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201,
evaluating gedatolisib in combination with darolutamide in patients
with metastatic castration resistant prostate cancer, is expected
to be initiated in the first quarter of 2024. The company's
CELsignia companion diagnostic platform is uniquely able to analyze
live patient tumor cells to identify new groups of cancer patients
likely to benefit from already approved targeted therapies. Further
information about Celcuity can be found at Celcuity.com. Follow us
on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc. Brian Sullivan,
bsullivan@celcuity.com Vicky Hahne,
vhahne@celcuity.com (763) 392-0123
ICR Westwicke Maria Yonkoski,
maria.yonkoski@westwicke.com (203) 682-7167
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Apr 2024 to May 2024
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From May 2023 to May 2024